DaShenLin Pharmaceutical Group Co., Ltd. (603233.SS)
CNY 16.16
(0.56%)
CNY 16.16
(0.56%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 1.16 Billion CNY | 12.63% |
| 2022 | 1.03 Billion CNY | 30.9% |
| 2021 | 791.23 Million CNY | -25.51% |
| 2020 | 1.06 Billion CNY | 51.17% |
| 2019 | 702.66 Million CNY | 32.17% |
| 2018 | 531.63 Million CNY | 11.93% |
| 2017 | 474.96 Million CNY | 10.41% |
| 2016 | 430.18 Million CNY | 8.79% |
| 2015 | 395.43 Million CNY | 48.94% |
| 2014 | 265.5 Million CNY | 34.51% |
| 2013 | 197.38 Million CNY | 32.31% |
| 2012 | 149.18 Million CNY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 259.14 Million CNY | -34.96% |
| 2024 Q1 | 398.45 Million CNY | 5169.17% |
| 2024 Q3 | 200.52 Million CNY | -22.62% |
| 2023 Q4 | -7.86 Million CNY | -103.06% |
| 2023 Q1 | 496.75 Million CNY | 222.22% |
| 2023 Q2 | 420.67 Million CNY | -15.32% |
| 2023 FY | 1.16 Billion CNY | 12.63% |
| 2023 Q3 | 256.93 Million CNY | -38.92% |
| 2022 Q2 | 329.96 Million CNY | -14.12% |
| 2022 FY | 1.03 Billion CNY | 30.9% |
| 2022 Q4 | 154.16 Million CNY | -26.25% |
| 2022 Q3 | 209.05 Million CNY | -36.64% |
| 2022 Q1 | 384.22 Million CNY | 1517.79% |
| 2021 Q1 | 340.55 Million CNY | 74.53% |
| 2021 Q3 | 172.68 Million CNY | -43.4% |
| 2021 FY | 791.23 Million CNY | -25.51% |
| 2021 Q2 | 305.09 Million CNY | -10.41% |
| 2021 Q4 | -27.1 Million CNY | -115.69% |
| 2020 Q3 | 272.32 Million CNY | -13.4% |
| 2020 Q2 | 314.46 Million CNY | 12.2% |
| 2020 FY | 1.06 Billion CNY | 51.17% |
| 2020 Q1 | 280.26 Million CNY | 91.33% |
| 2020 Q4 | 195.12 Million CNY | -28.35% |
| 2019 FY | 702.66 Million CNY | 32.17% |
| 2019 Q3 | 175.45 Million CNY | -10.78% |
| 2019 Q4 | 146.48 Million CNY | -16.51% |
| 2019 Q1 | 184.05 Million CNY | 56.45% |
| 2019 Q2 | 196.66 Million CNY | 6.85% |
| 2018 Q1 | 147 Million CNY | 35.8% |
| 2018 Q4 | 117.64 Million CNY | -6.65% |
| 2018 FY | 531.63 Million CNY | 11.93% |
| 2018 Q2 | 140.95 Million CNY | -4.12% |
| 2018 Q3 | 126.02 Million CNY | -10.59% |
| 2017 Q3 | 118.28 Million CNY | -9.83% |
| 2017 Q1 | 117.23 Million CNY | 23.07% |
| 2017 Q2 | 131.17 Million CNY | 11.89% |
| 2017 FY | 474.96 Million CNY | 10.41% |
| 2017 Q4 | 108.25 Million CNY | -8.48% |
| 2016 Q2 | 102.39 Million CNY | -10.69% |
| 2016 Q1 | 114.65 Million CNY | 0.0% |
| 2016 Q3 | 114.17 Million CNY | 11.5% |
| 2016 Q4 | 95.25 Million CNY | -16.57% |
| 2016 FY | 430.18 Million CNY | 8.79% |
| 2015 Q1 | 94.84 Million CNY | 0.0% |
| 2015 Q2 | 94.84 Million CNY | 0.0% |
| 2015 FY | 395.43 Million CNY | 48.94% |
| 2014 FY | 265.5 Million CNY | 34.51% |
| 2013 FY | 197.38 Million CNY | 32.31% |
| 2012 FY | 149.18 Million CNY | 0.0% |